MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents

MY Shah, E Martinez-Garcia, JM Phillip, AB Chambliss, R Popovic, T Ezponda, EC Small, C Will, MP Phillip, P Neri, NJ Bahlis, D Wirtz and JD Licht

INTRODUCTION

Multiple myeloma (MM), which accounts for 20% of deaths from hematologic malignancies, is a tumor of post-germinal center B cells that have undergone somatic hypermutation, antigen selection and immunoglobulin heavy-chain class switching. MM is often characterized by chromosomal translocations that link an oncogene with a strong immunoglobulin promoter/enhancer. Among these, the t(4;14) translocation, occurring in 15–20% of patients, leads to the overexpression of MMSET/WHSC1/NSD2. These patients have a poorer prognosis and response to therapy compared to other MM subtypes. MMSET was first identified in Wolf-Hirschhorn syndrome, characterized by growth deficiency, craniofacial abnormalities and developmental delays. MMSET is one of three NSD family members, all of which possess a SET domain and lysine methyltransferase activity. Overexpression of MMSET is also observed in neuroblastoma, prostate and breast cancer, and is associated with a poorer prognosis.

We showed previously that elevated levels of MMSET in t(4;14)+ MM lead to a global increase in histone 3 lysine 36 dimethylation (H3K36me2) and a concomitant decrease in histone 3 lysine 27 trimethylation (H3K27me3), as well as changes in proliferation, gene expression and chromatin accessibility. Prior work linked methylation of histones to the ability of cells to undergo DNA damage repair. In addition, t(4;14)+ patients frequently relapse after regimens that include DNA damage-inducing agents, suggesting that MMSET may play a role in DNA damage repair and response. In U2OS cells, we found that MMSET is required for efficient non-homologous end joining as well as homologous recombination. Loss of MMSET led to loss of expression of several DNA repair proteins, as well as decreased recruitment of DNA repair proteins to sites of DNA double-strand breaks (DSBs). By using genetically matched MM cell lines that had either high (pathological) or low (physiological) expression of MMSET, we found that MMSET-high cells had increased damage at baseline. Upon addition of a DNA-damaging agent, MMSET-high cells repaired DNA damage at an enhanced rate and continued to proliferate, whereas MMSET-low cells accumulated DNA damage and entered cell cycle arrest. In a murine xenograft model using t(4;14)+ KMS11 MM cells harboring an inducible MMSET shRNA, depletion of MMSET enhanced the efficacy of chemotherapy, inhibiting tumor growth and extending survival. These findings help explain the poorer prognosis of t(4;14) MM and further validate MMSET as a potential therapeutic target in MM and other cancers.
regulator of the DDR. MMSET also plays a role in class-switch recombination during B-cell development, accumulates at immunoglobulin gene-switch regions with H3K36me2 and yH2AX, and its depletion led to defects in class-switch recombination.

H3K36 methylation, created by MMSET and other SET domain proteins in vivo, can also influence DNA repair pathway choice. The SET domain protein SETMAR/Metnase deposits H3K36me2 at DSBs, enhancing association of non-homologous end joining (NHEJ) repair components at those sites. In yeast, loss of Set2/H3K36 methylation led to decreased DNA damage signaling and more open chromatin around DSBs. Set2 promoted Ku recruitment to damaged DNA and inhibited homologous recombination (HR), increasing NHEJ. In human cells, loss of the H3K36me3 methyltransferase SETD2 led to reduced DSB end resection and decreased recruitment of HR repair proteins such as RAD51.

Collectively, this background suggests that MMSET may modulate DNA repair and chemotherapy response in t(4;14)+ MM.

Here, we demonstrate that MMSET affects DNA repair when expressed at physiological and pathological levels. MMSET is necessary for both efficient NHEJ and HR repair in U2OS cells, and loss of MMSET leads to decreased expression of DNA repair genes, as well as decreased recruitment of DNA repair proteins to the site of damage. By using genetically matched MM cell lines differing only in their levels of MMSET expression, we found that MMSET promoted the survival and proliferation of cells in the face of DNA damage due to an enhanced rate of DNA repair. Loss of MMSET enhanced the efficacy of chemotherapy in a murine xenograft model, further substantiating MMSET as a therapeutic target.

**RESULTS**

MMSET participates in multiple pathways of DNA repair

To investigate the role of MMSET in NHEJ, U2OS cells were transfected with a linearized vector harboring a neomycin-resistant gene and an siRNA targeting MMSET. In the presence of neomycin, only cells that can integrate the plasmid via NHEJ survive. As expected, MMSET depletion led to decreased levels of H3K36 dimethylation and increased levels of H3K27 trimethylation (Figure 1a). Furthermore, knockdown of MMSET led to decreased formation of drug-resistant colonies (Figures 1b and c; Supplementary Figure 1a), suggesting that MMSET is important in NHEJ. In parallel, siRNA-mediated depletion of Ligase IV, which is required to form the NHEJ complex, led to an expected decrease in cell survival (Supplementary Figure 1b). To assess whether MMSET had a role in HR, cells were transfected with two mutant β-galactosidase (lacZ) plasmids. Only cells that repair the plasmids via HR express lacZ. Again, the efficiency of HR decreased when MMSET was depleted (Figure 1d and Supplementary Figure 1c).

By using a qPCR-based array, we found that knockdown of MMSET in U2OS cells led to decreased expression of many genes implicated in DNA repair pathways (Supplementary Figure 2a). We used two siRNAs directed against MMSET, one that was a pool of siRNAs (Supplementary Figure 2a, top) and one that was directed toward the C-terminal region of MMSET (Supplementary Figure 2a, bottom). Both siRNA reagents led to downregulation of many of the same genes, including DDIT3, PRKDC, MSH2, MSH3, XRCC2, BARD1 and BLM. We confirmed that MMSET knockdown did not affect cell cycle progression in U2OS cells (Supplementary Figure 2b) and therefore the changes in DNA repair were not simply related to changes in cell proliferation.

The U2OS cells were engineered to express the AsiSI enzyme fused to an estrogen receptor hormone-binding domain. Upon 4-hydroxytamoxifen (4-OHT) treatment, the enzyme translocates into the nucleus to induce DSBs at AsiSI sites throughout the genome. We confirmed an increase in yH2AX levels after addition of 4-OHT (Supplementary Figure 2c). Upon MMSET depletion there was decreased expression of RAD51 and 53BP1 (Figure 2a), and this depletion was not altered by DSB induction. We also observed loss of CtIP expression (data not shown). By contrast, no loss of...
expression of XRCC4 and Ku80 was observed (Figure 2a). RAD51 binds the ends of single-stranded DNA during HR, whereas 53BP1 is a regulator of the DSB response. XRCC4 and Ku80 complex with Ligase IV to promote end joining in NHEJ. We performed chromatin immunoprecipitation (ChIP) and monitored a specific AsiSI-induced DSB site for recruitment of DNA repair proteins. After MMSET knockdown, we observed increased levels of γH2AX, a well-established indicator of DNA damage (Figures 2b and e). Simultaneously, XRCC4 recruitment was decreased (Figures 2c and e) even though its protein expression was unchanged. ChIP showed that RAD51 was recruited to this DSB but this failed to occur with MMSET knockdown (Figures 2d and e), likely due to the striking loss of RAD51 protein expression. These findings imply that MMSET is important for regulating expression of certain DNA repair proteins in both major repair pathways, and may facilitate recruitment of DDR proteins to DSBs.

MMSET extends a proliferative advantage in MM cells treated with a DNA-damaging agent

To study the effects of MMSET on the DDR in MM, we used two cell lines derived from the t(4;14)+ KMS11 myeloma cell line and manipulated by HR-mediated gene disruption. Non-targeted knockout, or MMSET-low cells, express only the wild-type (wt) allele (Supplementary Figure 3a). When treated with a modest dose of the DNA crosslinking agent melphalan (0.5 μM; Figures 3a and b) or the DSB inducer bleomycin (Supplementary Figure 3b and 3c), MMSET-high cells had increased proliferation and formed more colonies. On the basis of the differences in proliferation, we next determined whether a checkpoint response and cell cycle arrest was occurring. At baseline, both cell lines showed a similar cell cycle profile (Figures 3c (left) and d). MMSET-low cells treated with melphalan had a significant decrease of cells in S-phase and an accumulation of cells in G2/M (Figures 3c and d, right), in accordance with prior findings. However, even when treated for an extended time, MMSET-high cells continued to progress through the cell cycle. Treatment of these cells with bleomycin and monitoring response by immunoblot for ATM, DNA-PK and Chk1 showed that both cell lines activated DDR pathways in a similar manner (Supplementary Figure 3d), suggesting that both cell types were sensing and responding to DNA damage. Nevertheless, cell cycle arrest only occurred in MMSET-low cells.

MMSET-high cells have increased DNA damage at baseline and enhanced repair

Since DDR signaling appeared intact in MMSET-high and -low cells, we determined whether the differential response of the cells
could be due to differences in the handling of DNA damage. MMSET-high and -low cell lines were treated with bleomycin for 1 h, collected either immediately after treatment or washed, fed with drug-free media and collected 1 h later. Intriguingly, at baseline before treatment, MMSET-high cells demonstrated higher levels of DNA damage, as measured by the alkaline comet assay (Figures 4a (top) and b). This was corroborated by immunostaining the MMSET-high and -low cells for 53BP1, which binds to damaged chromatin (Figures 4c and d). After 1 h of bleomycin treatment, both cell types had increased levels of DNA damage as assayed by tail moment compared to untreated (Figure 4a, middle), but 1 h after drug release, MMSET-high cells displayed a
much shorter tail moment, indicating a significantly greater extent of DNA repair (Figures 4a (bottom) and b). MMSET-low cells still had a significant increase in tail length after drug release. Similar results were found when these cells were treated with melphalan (Supplementary Figure 3e).

Next, MMSET-low (targeted knockout) cells were repleted using retroviruses harboring wt MMSET or an histone methyltransferase (HMT) inactive form (Y1118A) of MMSET. Targeted knockout cells overexpressing wt MMSET had higher levels of baseline DNA damage than cells infected with the control vector. Importantly, the HMT-inactive mutant did not induce increased DNA damage (Supplementary Figures 4a and b). When cells were treated with a pulse of melphalan for 1 h and collected at 0 and 24 h post release, we again observed that cells with wt MMSET repaired DNA damage more rapidly (Supplementary Figure 4b). Targeted knockout cells overexpressing wt MMSET displayed increased survival when continuously treated with melphalan than did cells containing the vector or HMT-inactive mutant (Supplementary Figure 4c). These data suggest that the increased survival of MMSET overexpressing cells after DNA-damaging agents is linked to accelerated DNA repair and that HMT activity of MMSET is critical for its role in DDR in MM.

MMSET-high cells have increased rates of DNA damage and repair

To further examine the induction and resolution of DNA damage in MM cells, we performed kinetic experiments (Figure 5) in which MMSET-high and -low cells were treated with bleomycin and assayed for γH2AX protein expression over time. In MMSET-high cells, a dramatic increase in γH2AX expression was seen immediately following bleomycin release, which returned to baseline levels after 2 h (Figure 5a). This effect was amplified with higher concentrations of bleomycin. However, in MMSET-low cells, no γH2AX expression was observed at the lower concentration of bleomycin. Even at the higher concentration, γH2AX expression was not seen until 30 min following drug release and continued to increase over time (Figure 5a). These data extend the results of the comet assay and suggest that MMSET-high cells have a higher baseline level of DNA damage, and accumulate more DNA damage after a genotoxic insult.

We further attempted to define differences in DNA damage and repair kinetics using a high-throughput single-cell phenotyping platform to elucidate cell cycle-dependent contributions on the DDR. DNA damage and repair kinetics were evaluated by the total γH2AX content present within the nucleus (per single cell) at baseline and after bleomycin treatment (Figures 5b–d) and by using linear regression of the change in γH2AX content as a function of time, we quantified the rates of DNA damage and repair. MMSET-high cells displayed an increased rate of DNA damage as seen by a fivefold increase in γH2AX content relative to MMSET-low cells (Figure 5c, left and Supplementary Figures 5a and b). The rate of accumulation of γH2AX content/time was significantly increased for all phases of the cell cycle in MMSET-high cells (Figure 5c, middle panel) versus MMSET-low cells (Figure 5c, right panel and Supplementary Figures 5a and b). Furthermore, actively cycling cells in G2/M showed higher rates of damage relative to cells in G0/G1 and S-phases in both MMSET-high and -low cells, which may be attributed to differences in the chromatin state as a function of cell cycle progression. DNA repair rates were evaluated by the loss of γH2AX signal per single nuclei following bleomycin removal. When cells across all phases of the cell cycle were examined there was a trend toward higher repair rates in MMSET-high cells (Figure 5d, left). Upon closer
examination of cells in each phase of the cell cycle, there was an elevated rate of repair in MMSET-high cells in G0/G1 (when NHEJ is active) and G2/M (when HR may occur) as measured by the rate of loss of γH2AX expression, but not S-phase (Figure 5d, compare middle and right panels; Supplementary Figures 5a and b). Together, these experiments confirm that MMSET-high cells have increased levels of DNA damage at baseline, demonstrate that MMSET-high cells can tolerate higher levels of DNA damage and accumulate DNA damage at a higher rate, and repair damage faster than MMSET-low cells.

MMSET-low cells have delayed restoration of chromatin architecture after induced DNA damage

For the DDR to ensue, chromatin is reorganized according to the ‘access, repair, restore’ model. DNA damage is recognized, chromatin remodeling occurs to allow DNA repair proteins to access the damage and finally, the original chromatin architecture is restored. Histone dynamics, including histone variants like γH2AX, are important in the DDR and histone chaperones and other chromatin remodelers are required to disassemble and reassemble chromatin during these phases. We hypothesized that MMSET may

Figure 5. MMSET-high cells have higher levels of DNA damage and an increased rate of DNA repair. (a) Immunoblot showing γH2AX levels in MMSET-high and -low cells. Cells were either untreated or treated for 1 h with a low (0.33 μg/ml) or high (3.3 μg/ml) concentration of bleomycin, washed and then collected at 0, 30, 60 and 120 min after drug washout. Total H2AX is a control for γH2AX and H4 is used as a loading control. (b–d) High-throughput cell phenotyping was performed on MMSET-high and -low cells using γH2AX content to determine rates of DNA damage and repair. Cells were treated continuously with 0.33 μg/ml bleomycin for up to 24 h and γH2AX levels were assessed in each phase of the cell cycle. (b) Left: representative image of single cells showing fluorescent staining of γH2AX foci (green). Right: merged image with DAPI (blue) for DNA content. (c) DNA damage rates and (d) DNA repair rates in MMSET-high and -low cells. In (c) and (d), the left graph shows the overall rate of DNA damage or repair for MMSET-high (blue) and -low (red) cells. The middle (MMSET high) and right (MMSET low) graphs show the rate of damage or repair in each phase of the cell cycle. G0/G1, green; S-phase, red; G2/M, blue.
affect nucleosome disruption caused by DSBs, which can be monitored by loss and regain of the H2A/H2B histone dimer \(^{42,43}\) at Alu sequences.\(^{44}\) These repetitive elements position nucleosomes with the central and 3'-flanking regions being nucleosome-free,\(^{45}\) thus showing increased sensitivity to DNA damage.\(^{45–47}\) MMSET-high and -low cells were treated with a pulse of bleomycin (3.3 \(\mu\)g/ml) for 1 h, washed and collected at 0 min, 30 min, 1 h and 2 h after release. ChIP–qPCR was performed over Alu repeat sequences to determine occupancy of H2B, H3 and \(\gamma\)H2AX in (a) MMSET-high and (b) MMSET-low cells. The average \(\pm\) s.e.m. is shown for three independent experiments. *\(P < 0.03; **P < 0.008\) by Student’s t-test. (c) Average relative enrichment \(\pm\) s.e.m. of \(\gamma\)H2AX at each time point relative to 0 min after drug release in MMSET-high and -low cells.

Loss of MMSET combined with chemotherapy in mice leads to decreased tumor size and increased survival

The increased repair capacity and survival of MMSET-high cells after chemotherapy represents a barrier to effective therapy for t(4;14)+ MM. Increased DNA repair by MMSET requires its HMT activity. Accordingly, loss of MMSET expression or the application of a potential MMSET enzyme inhibitor would be predicted to enhance chemotherapy efficacy. To test this idea, we injected nude mice with t(4;14)+ KMS11 cells tagged with luciferase and expressing a doxycycline-inducible shRNA targeting MMSET\(^8,10\) (Figure 7). Tumors formed over 2 weeks, after which mice were left untreated, administered doxycycline to downregulate MMSET expression, administered melphalan chemotherapy, or were given both treatments. Treatments were administered for 4 weeks, and mice were monitored non-invasively for an additional 4 weeks.
Untreated mice had rapidly growing tumors and were killed due to tumor burden (Figures 7a and b). Knockdown of MMSET slowed tumor progression and melphalan chemotherapy had a similar effect on survival (Figure 7b). Strikingly, the combination of MMSET knockdown and melphalan led to decreased tumor size (Figure 7a) and increased survival (Figure 7b), with several mice experiencing complete tumor regression. This suggests that MMSET inhibition might synergize with other therapies in MM patients.

DISCUSSION
Our work and that of others provide growing evidence that MMSET and histone methylation are important for DNA repair. In U2OS cells, loss of MMSET leads to less-efficient NHEJ and HR (Figure 1), correlating with decreased expression of specific DNA repair genes and decreased recruitment of particular DNA repair proteins to DSBs (Figure 2). This suggests that MMSET may act as a transcriptional co-factor to assure the transcription of key DDR genes.
components. This does not exclude other modes of action and how MMSET may affect recruitment of factors to sites of DNA damage is not yet understood. Along these lines, when we isolated MMSET partner proteins in 293 cells, we identified KAP1, which has been implicated in the DDR, suggesting that MMSET may assist in recruitment of some DDR components to chromatin. Recent work has shown that MMSET is recruited to DSBs as part of a larger protein complex, which results in chromatin remodeling and recruitment of RAD51 to the DSB site. Alternately, the loss of expression of key constituents of the DDR pathways, such as CtIP, may lead to inefficient recruitment of other DDR proteins, like XRCC4, to DNA lesions. For example, loss of the histone chaperone nucleolin led to reduced recruitment of XRCC4, abrogating repair at DSB sites.

The role of MMSET in the normal DDR may not be reflective of effects of pathological overexpression of MMSET in MM. High levels of MMSET lead to altered gene expression, including expression of DNA repair genes, but whether the modest increase in DDR genes that we observed in t(4;14) cells can explain the increased rates of DNA damage at baseline and after genotoxic insult is uncertain. Furthermore, there are still conflicting data regarding MMSET and the role of the specific histone marks it makes in relation to DNA repair. Although some groups showed that MMSET might accumulate at DSBs and induce H4K20 methylation at those sites, resulting in recruitment of 53BP1, two independent groups showed that MMSET had no effect on H4K20 methylation or 53BP1 formation. We, and others, have not observed MMSET-induced H4K20 methylation in vivo and instead find that H3K36 is the main target of MMSET. A number of studies have shown that the H3K36 mark helps determine DNA repair pathway choice, favoring NHEJ. We showed that the global increase of H3K36me2 and decrease of H3K27me3 across the genome due to MMSET overexpression was associated with a more open chromatin state characterized by increased chromatin susceptibility to micrococcal nuclease. The open chromatin of MMSET-high cells may allow DNA to be more accessible to damaging agents, including the genotoxic stresses experienced by cells in culture. In support of this idea, single-cell analysis showed that MMSET-high cells had increased baseline levels of γH2AX and accumulated more of this modification, reflecting increased DNA damage, when treated with bleomycin (Figure 3). The increased accessibility of chromatin in t(4;14) cells would also allow the DNA repair machinery to more rapidly access lesions, thus facilitating repair of the breaks and restoration of normal chromatin structure to an intact, undamaged state. Alu repeat sequence analysis supported this idea with MMSET-high cells showing more rapid restoration of chromatin (Figure 6). Given that DDR signaling pathways appeared intact in both MMSET-high and -low cells, we propose that the rapid DNA repair of MMSET-high cells underlies their relative insensitivity to genotoxic chemotherapy.

There is precedent for the physical status of chromatin altering the efficiency of DNA repair. Embryonic stem cells have a more open chromatin structure with more chromatin remodeling occurring at any given time. Accordingly, murine embryonic stem cells demonstrate a high level of DNA single-strand breaks and γH2AX accumulation, which was attributed to global chromatin decondensation. Increased levels of histone acetylation characterize transcriptionally active euchromatin and use of histone deacetylase inhibitors (HDACi) leads to a more relaxed chromatin state and increased gene expression. Treating leukemia cells with the HDACi trichostatin A led to DNA damage in regions of DNA containing H4 acetylation and stimulated apoptosis as a result of that damage in leukemic cells. Treating cancer cells with a different HDACi, vorinostat, also led to increased γH2AX levels. Normal cells could repair DSBs upon HDACi removal, but cancer cells could not, which was attributed to decreased expression of DNA repair proteins. These examples all support the idea that altered chromatin structure can lead to increased DNA damage and altered DNA repair in cancer cells.

Melphalan resistance in MM has been associated with enhanced DNA repair. The melphalan-resistant cell line RPMI8226-LRS demonstrated upregulated expression of NHEJ proteins, including XRCC4. Melphalan-resistant cells had an increased number of cells with γH2AX foci compared to sensitive cells, and the resistant cells showed a greater decrease in the number of γH2AX foci over time. A connection between chemotherapy resistance and enhanced DNA repair has also been documented in other malignancies. In a mouse lung cancer model, prolonged treatment with cisplatin led to drug resistance, elevated expression of DNA damage repair genes and enhanced DNA repair. The endonuclease Apel/Ref-1, a key component for base excision repair, can be elevated in human gliomas, contributing to alkylating agent chemotherapy resistance. These findings support our data showing that loss of MMSET leads to a decrease in repair protein expression (Figure 2) and that MMSET-high cells can repair DNA damage more quickly than MMSET-low cells (Figures 4 and 5). In addition to MM, neuroblastoma, prostate, breast and ovarian cancers also have high levels of MMSET. Our findings show that MMSET enhances multiple pathways of DNA repair and provides a rational target for therapy. The search for an MMSET inhibitor is already underway and could prove fruitful for MM and other cancers.

MATERIALS AND METHODS

See also Supplementary Materials and Methods.

Cell culture

U2OS cells harboring the pBabe-AsiS-ER vector were grown in DMEM with 10% heat-inactivated fetal bovine serum, 25 mM HEPES and antibiotics. Cells were treated with 300 nM 4-hydroxytamoxifen for 6–8 h to induce DSBs. All MM cell lines were cultured in RPMI as previously described and treated with varying concentrations of melphalan or bleomycin.

NHEJ assay

U2OS cells were transfected with siScramble, siMMSET pool or siLigase IV. After 24 h of transfection, cells were transfected with BamHI-XhoI linearized pEGER-C1 (Clontech, Mountain View, CA, USA). The next day, cells were trypsinized, counted and plated. Cells with and without G418 (0.5 mg/ml) were incubated for 14 days at 37°C and colonies were visualized with 0.05% crystal violet, 1% formaldehyde and 1% methanol. Quantification was performed using ImageJ (https://imagej.nih.gov/ij/).

HR assay

An HR assay (Norgen Biotek, Thorold, ON, Canada) was performed in U2OS cells after transfection with siScramble, siMMSET pool or siLigase IV. On day 5 of knockdown, cells were trypsinized and 1 × 10^6 cells were replated. On day 6, cells were transfected using TurboFect (Thermo Scientific, Pittsburgh, PA, USA) with 2.5 μg of positive control plasmid or 2.5 μg each of dl-1 and dl-2 plasmids. After 24 h of transfection, DNA was isolated using the Wizard genomic DNA purification kit (Promega, Madison, WI, USA). qPCR (primer sequences in Supplementary Table 1) was performed on a Roche LightCycler 480 II using the assay primers from the kit and LightCycler 480 SYBR Green I Master (Roche Applied Science, Indianapolis, IN, USA). GAPDH was used for normalization.

Comet assays

Cells were processed using the CometAssay kit (Trevigen, Gaithersburg, MD, USA). Images were obtained using a Leica DFC320 microscope camera with Leica Application Suite V4.4 software (Leica Microsystems, Wetzlar, Germany). At least 100 cells were analyzed per sample using CometScore (TriTek Corp., Sumnerduck, VA, USA).
High-throughput cell phenotyping
MM cells were seeded at a density of 2 × 10^5 cells into six-well plates and treated with 0.33 μM SET and incubated with 0.33 μM SET in (4/14) multiple myeloma cells. Blood 2011; 117: 211–220.
Zheng Y, Svet T, Poppovic R, Martinez-Garcia E, Tipnot JD, Thomas PM et al. Total kinetic analysis reveals how combinatorial methylation patterns are established on lysines 27 and 36 of histone H3. Proc Natl Acad Sci USA 2012; 109: 13549–13554.
Poppovic R, Martinez-Garcia E, Giannopoulos E, Zhang Q, Eozen T, Shah NY et al. Histone methylation transferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation. PLoS Genet 2014; 10: e1004566.
Laurin J, Aukberg AM, Konihi H, Garay JP, Gustin WP, Wang Q et al. The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. Blood 2008; 111: 856–864.
Kuo AJ, Cheung P, Chen K, Zee BM, Koi M, Laurin J et al. NSD2 links dimethyl- lation of histone H3 lysine 36 to oncogenic programming. Mol Cell 2011; 44: 609–620.
Gourzounis-Dmitriev C, Kamassara A, Sahota S, Reme T, Moreaux J, Bourguard P et al. DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment. Cell Cycle 2013; 12: 2760–2773.
Palumbo A, Cavalli F, Gay D, Fi Raimondo F, Ben Yehuda D, Petretti M et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 2014; 371: 895–905.
Jaksic W, Trudel S, Chang H, Trieu Y, Qi X, Mikhail J et al. Clinical outcomes in (4/14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol 2005; 23: 7069–7073.
Roussel M, Moreau P, Huyh A, Mary JY, Danho C, Caillot D et al. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood 2010; 115: 32–37.
Cook G, Williams C, Brown JM, Cairns DA, Cavenagh J, Snowden JA et al. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 874–885.
Hadju I, Cecia A, Lewis SM, Elledge SJ. Wolf-Hirschhorn syndrome candidate 1 is involved in the cellular response to DNA damage. Proc Natl Acad Sci USA 2011; 108: 13130–13134.
Pei H, Zhang L, Luo K, Qin Y, Chesi M, Fei F et al. MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature 2011; 470: 124–128.
Pei H, Wu X, Liu T, Yu K, Jelinek DF, Lou Z. The histone methylation transferase MMSET regulates class switch recombination. J Immunol 2013; 190: 756–763.
Frus S, Williamson EA, De Haro LP, Brenneman M, Wray J, Shaheen M et al. Methylation of histone H3 lysine 36 enhances DNA repair by nonhomologous end-joining. Proc Natl Acad Sci USA 2011; 108: 540–545.
Jia DK, Strahl BD. An RNA polymerase II-coupled function for histone H3K36 methylation in checkpoint activation and DSB repair. Nat Commun 2014; 5: 3965.
Pai CC, Deegan RS, Subramanian L, Gal C, Sarkar S, Blakely EJ et al. A histone H3K36 chromatin switch coordinates DNA double-strand break repair pathway choice. Nat Commun 2014; 5: 4091.
Aymard F, Bugler B, Schmidt CK, Guillou E, Caron P, Briou S et al. Transcriptionally active chromatin recruits homologous recombination at DNA double-strand breaks. Nat Struct Mol Biol 2014; 21: 366–374.
Carvalho S, Vitor AC, Sridha SC, Martins FB, Raposo AC, Desterro JM et al. SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint. Elife 2014; 3: e02482.
Pfister SX, Alsabi M, Zalmas LP, Sarkar S, Aymard F, Bachrati CZ et al. SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability. Cell Rep 2014; 7: 2006–2018.
Miller RM, Tjroms VV, Coates JS, Legube P, Pullo SE, Britton S et al. Human HDAC1 and HDAC2 function in the DMD in vivo response to promote DNA nonhomologous end-joining. Nat Struct Mol Biol 2010; 17: 1144–1151.
Ezponda T, Poppovic R, Shah NY, Martinez-Garcia E, Zheng Y, Min DJ et al. The histone methylation transferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer. Oncogene 2013; 32: 2862–2869.
Iacovoni JS, Caron P, Lassau N, Nicolas E, Massip L, Trouche D et al. High-resolution profiling of gammaH2AX foci and DNA double strand breaks in the mammalian genome. EMBO J 2010; 29: 1446–1457.
31 Panier S, Boulton SJ. Double-strand break repair: S3BP1 comes into focus. Nat Rev Mol Cell Biol 2014; 15: 7–18.
32 Li L, Robert C, Rassool FV. The role of error-prone alternative non-homologous end-joining in genomic instability in cancer. In: Vengrova S (ed). DNA Repair and Human Health. InTech: Rijeka, Croatia, 2011.
33 Povirk LF, Han YH, Steigler RJ Jr. Structure of bleomycin-induced DNA double-strand breaks: predominance of blunt ends and single-base 5' extensions. Biochemistry 1989; 28: 5808–5814.
34 Lupo M, Cappella P, Materia G, Notoli C, Ubezio P. Interpreting cell cycle effects of drugs: the case of melphalan. Cancer Chemother Pharmacol 2006; 57: 443–457.
35 Liao W, McNutt MA, Zhu W. The comet assay: a sensitive method for detecting DNA damage in individual cells. Methods 2009; 48: 46–53.
36 Chambliss AB, Wu PH, Chen WC, Sun SX, Wirtz D. Simultaneously defining cell phenotypes, cell cycle, and chromatin modifications at single-cell resolution. FASEB J 2013; 27: 2667–2676.
37 Guo Q, Phillip JM, Majumdar S, Wu PH, Chen J, Calderon-Colon X et al. Modulation of keratocyte phenotype by collagen fibril nanoarchitecture in membranes for corneal repair. Biomaterials 2013; 34: 9365–9372.
38 Chen WC, Wu PH, Phillip JM, Khatau SB, Choi JM, Dallas MR et al. Functional interplay between the cell cycle and cell phenotypes. Integr Biol 2013; 5: 523–534.
39 Sulli G, Di Micco R, d’Adda di Fagagna F. Crosstalk between chromatin state and DNA damage signaling and double-strand break repair. J Mol Cell Biol 2013; 5: 157–165.
40 Ransom M, Dennehey BK, Tyler JK. Chaperoning histones during DNA replication and repair. Cell 2010; 140: 183–195.
41 Soria G, Polo SE, Almouzni G. Prime, repair, restore: the active role of chromatin in the DNA damage response. Mol Cell 2012; 46: 722–734.
42 Berkovich E, Monnat RJ Jr, Kastan MB. Roles of ATM and NBS1 in chromatin structure modulation and DNA double-strand break repair. Nat Cell Biol 2007; 9: 683–690.
43 Goldstein M, Derheimer FA, Tait-Mulder J, Kastan MB. Nucleolin mediates nucleosome disruption critical for DNA double-strand break repair. Proc Natl Acad Sci USA 2013; 110: 16874–16879.
44 Deininger P. Alu elements: know the SINEs. Genome Biol 2011; 12: 236.
45 Englander EW, Howard BH. Nucleosome positioning by human Alu elements in chromatin. J Biol Chem 1995; 270: 10091–10096.
46 Englander EW, Wolfe AP, Howard BH. Nucleosome interactions with a human Alu element. Transcriptional repression and effects of template methylation. J Biol Chem 1993; 268: 19565–19573.
47 Englander EW, Howard BH. Alu-mediated detection of DNA damage in the human genome. Mutat Res 1997; 385: 31–39.
48 Mao Z, Hine C, Tian X, Van Meter M, Au M, Vaidya A et al. SIRT6 promotes DNA repair under stress by activating PARP1. Science 2011; 332: 1443–1446.
49 Min DJ, Espota T, Kim MK, Will CM, Martinez-Garcia E, Popovic R et al. MMSET enhances DNA repair in multiple myeloma. Oncogene (2016) 1

Supplementary Information accompanies this paper on the Oncogene website (http://www.nature.com/onc)